We believe our proprietary Carrierwave™ technology can be applied in various ways to improve existing drugs. We refer to our Carrierwave™ compounds as Conditionally Bioreversible Derivatives (CBDs). We create a new molecule—a derivative—made of the active pharmaceutical ingredient of a drug such as an amphetamine or opioid, covalently attached to an adjuvant. We design the new molecules to be pharmacologically inactive and only activated ("bioreversed") when taken as directed.